BR0212354A - Inibição por 3-deoxiflavonóides da ativação dos linfócitos-t e terapias relacionadas com ela - Google Patents
Inibição por 3-deoxiflavonóides da ativação dos linfócitos-t e terapias relacionadas com elaInfo
- Publication number
- BR0212354A BR0212354A BR0212354-1A BR0212354A BR0212354A BR 0212354 A BR0212354 A BR 0212354A BR 0212354 A BR0212354 A BR 0212354A BR 0212354 A BR0212354 A BR 0212354A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- deoxyflavonoid
- rutin
- inhibition
- lymphocyte activation
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 2
- 230000004913 activation Effects 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 abstract 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 abstract 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 abstract 2
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 abstract 2
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 abstract 2
- 235000009498 luteolin Nutrition 0.000 abstract 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 abstract 2
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 abstract 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 abstract 2
- 235000005493 rutin Nutrition 0.000 abstract 2
- 229960004555 rutoside Drugs 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 239000000039 congener Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000010579 first pass effect Methods 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003306 rutin derivatives Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
- C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
- C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrane Compounds (AREA)
Abstract
"INIBIçãO POR 3-DEOXIFLAVONóIDES DA ATIVAçãO DOS LINFóCITOS-T E TERAPIAS RELACIONADAS COM ELA". Compostos de 3-deoxiflavanóide e métodos para inibir a atividade das células-T e tratar doenças e distúrbios (p. ex., distúrbios autoimunes, distúrbios inflamatórios, diabetes, ALS, MS, artrite reumatóide etc.). Em alguns casos, a eficácia e/ou duração da ação da luteolina e/ou outros compostos de 3-deoxiflavonóide podem ser aumentadas pela administração de tais compostos juntamente com Rutina, um congênere da Rutina e/ou um derivado da Rutina. Também em alguns casos o metabolismo de primeira passagem da luteolina ou outros 3-deoxiflavanóides pode ser evitado administrando-se tais compostos por vias parenterais (P. ex., sublingual, bucal, intranasal, injeção etc.).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31766601P | 2001-09-06 | 2001-09-06 | |
| US40712502P | 2002-08-30 | 2002-08-30 | |
| PCT/US2002/028348 WO2003022994A2 (en) | 2001-09-06 | 2002-09-06 | Inhibition by 3-deoxyflavonoids of t-lymphocyte activation and therapies related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0212354A true BR0212354A (pt) | 2004-11-30 |
Family
ID=26981074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0212354-1A BR0212354A (pt) | 2001-09-06 | 2002-09-06 | Inibição por 3-deoxiflavonóides da ativação dos linfócitos-t e terapias relacionadas com ela |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6774142B2 (pt) |
| EP (1) | EP1429750B1 (pt) |
| JP (1) | JP2005504796A (pt) |
| KR (1) | KR20040048407A (pt) |
| CN (1) | CN1668287B (pt) |
| AT (1) | ATE476178T1 (pt) |
| AU (1) | AU2002332878A1 (pt) |
| BR (1) | BR0212354A (pt) |
| DE (1) | DE60237213D1 (pt) |
| MX (1) | MXPA04002077A (pt) |
| WO (1) | WO2003022994A2 (pt) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040102386A1 (en) * | 2001-09-06 | 2004-05-27 | Thomas Lahey | Inhibition by 3-deoxyflavonoids of T-lymphocyte activation and therapies related thereto |
| DE10359384A1 (de) * | 2003-12-18 | 2005-07-28 | Anoxymer Gmbh | Verwendung eines Extraktes von Aloysia triphylla als Matrixprotektor |
| WO2006005173A1 (en) * | 2004-07-09 | 2006-01-19 | Medicure International Inc. | Combination therapies employing nicotinic acid derivatives or fibric acid derivatives |
| WO2006030322A2 (en) * | 2004-09-17 | 2006-03-23 | University Of Manitoba | Use of fla vone/fla vanone derivatives fn the treatment or prevention of respiratory conditions |
| AU2006222556B2 (en) * | 2005-03-11 | 2011-09-29 | Armaron Bio Pty Ltd | Flavonoid compounds and uses thereof |
| AU2006245071A1 (en) * | 2005-05-06 | 2006-11-16 | Amino Up Chemical Co., Ltd. | Health food and pharmaceutical composition for amelioration of disease induced by metabolic disorder in cartilage |
| JP2009515943A (ja) * | 2005-11-17 | 2009-04-16 | ファイザー・リミテッド | アミノ酸誘導体 |
| KR100817662B1 (ko) | 2006-03-23 | 2008-03-27 | 주식회사 엘지생활건강 | ｃ-Ｋｉｔ 활성 저해제, 피부미백제 및 이를 함유하는피부미백용 조성물 |
| US8623871B2 (en) * | 2006-01-25 | 2014-01-07 | Synta Pharmaceuticals Corp. | Substituted biaryl compounds for inflammation and immune-related uses |
| US8741960B2 (en) * | 2006-01-25 | 2014-06-03 | Synta Pharmaceuticals Corp. | Substituted aromatic compounds for inflammation and immune-related uses |
| CA2693338A1 (en) * | 2007-07-31 | 2009-02-05 | Limerick Biopharma, Inc. | Phosphorylated pyrone analogs and methods |
| EP2182801A4 (en) * | 2007-07-31 | 2011-04-13 | Limerick Biopharma Inc | COMPOSITIONS OF PYRONE ANALOGS AND METHODS |
| GB0805312D0 (en) * | 2008-03-20 | 2008-04-30 | Medical Res Council | Modulation of the immune response |
| CA2738328A1 (en) * | 2008-08-29 | 2010-03-04 | Novogen Research Pty Ltd | Immunomodulating activities |
| AU2009303300A1 (en) * | 2008-10-10 | 2010-04-15 | Limerick Biopharma, Inc. | Pyrones for the treatment of metabolic disorders |
| EP2424541A2 (en) * | 2009-04-27 | 2012-03-07 | Limerick BioPharma, Inc. | Phosphorylated and phosphonated pyrone analogs for therapeutic treatment |
| JP5594719B2 (ja) * | 2010-01-06 | 2014-09-24 | 国立大学法人神戸大学 | 筋肉の糖取り込み促進剤 |
| EP2635121B1 (en) | 2010-11-01 | 2020-01-08 | MEI Pharma, Inc. | Isoflavonoid compounds and methods for the treatment of cancer |
| EP2741609A4 (en) * | 2011-08-12 | 2015-04-08 | Salk Inst For Biological Studi | NEUROPROTECTIVE POLYPHENOLANALOGA |
| CN102872155B (zh) * | 2012-10-30 | 2014-04-02 | 中国人民解放军第四军医大学 | 一种黄酮苷类化合物在制备治疗脑中风药物中的应用 |
| KR101497935B1 (ko) * | 2013-04-19 | 2015-03-03 | 경북대학교 산학협력단 | 루테올린을 유효성분으로 포함하는 섬유증의 예방 또는 치료용 조성물 |
| EP2894200A1 (en) * | 2014-01-13 | 2015-07-15 | Rubia Exploitatie B.V. | Process for production of a dye preparation |
| CN104387360B (zh) * | 2014-11-21 | 2016-10-05 | 潍坊医学院 | 柚皮素脂肪酸酯、其制备方法和以该化合物为活性成分的药物组合物及其应用 |
| PL3253208T3 (pl) | 2015-02-02 | 2021-11-08 | Mei Pharma, Inc. | Terapie kombinowane do zastosowania w leczeniu nowotworu piersi |
| US11224588B2 (en) * | 2015-05-21 | 2022-01-18 | Ophtalmis Monaco | Combination of lipoic acid and taurine as osmoprotective agent |
| CN108395461B (zh) * | 2017-02-07 | 2022-01-07 | 浙江康恩贝制药股份有限公司 | 7,4′-O-β-D-葡萄糖桑色素苷及其制备和其在制备抗炎药物中的应用 |
| GB201811312D0 (en) * | 2018-07-10 | 2018-08-29 | Nuchido Ltd | Compositions |
| CN109265424B (zh) * | 2018-09-25 | 2020-08-21 | 天津中医药大学 | 一种黄酮类衍生物及其制备方法和鉴定方法 |
| JP2022514470A (ja) * | 2018-12-14 | 2022-02-14 | エフ．ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎ウイルス感染症を治療および予防するためのクロマン－４－オン誘導体 |
| CN109620771B (zh) * | 2018-12-19 | 2022-08-26 | 浙江奥比特生物科技有限公司 | 一种肌肤抗炎祛痘的化妆品组合物及其产品 |
| CN110642825B (zh) * | 2019-10-16 | 2021-06-15 | 中国海洋大学 | 一种黄酮类衍生物及其制备方法和在制备免疫增强剂中的应用 |
| CN111978330B (zh) * | 2020-09-03 | 2023-08-22 | 中国科学院昆明植物研究所 | 黄烷醇-脂肪醇杂合体及其药物组合物与其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3867541A (en) | 1972-05-03 | 1975-02-18 | Ralph C Robbins | Compositions and methods for disaggregating blood cells |
| JPS5899414A (ja) * | 1981-12-10 | 1983-06-13 | Jun Okuda | アルド−スレダクタ−ゼの阻害剤 |
| JP2544734B2 (ja) * | 1987-03-24 | 1996-10-16 | コスモ開発株式会社 | 免疫抑制剤 |
| JPH03232851A (ja) * | 1989-12-26 | 1991-10-16 | Nippon Flour Mills Co Ltd | アルドース還元酵素阻害剤 |
| JPH05286962A (ja) * | 1992-02-14 | 1993-11-02 | Kyowa Hakko Kogyo Co Ltd | ５−アミノフラボン誘導体 |
| JPH08104628A (ja) * | 1994-10-04 | 1996-04-23 | Sumitomo Pharmaceut Co Ltd | マトリックスメタロプロテアーゼ阻害剤 |
| WO1996024592A1 (fr) * | 1995-02-06 | 1996-08-15 | Kyowa Hakko Kogyo Co., Ltd. | Derives 5-aminoflavone |
| JPH09176011A (ja) * | 1995-12-27 | 1997-07-08 | Kureha Chem Ind Co Ltd | Ｈｓｐ２７ファミリーに属するタンパク質のフラボノイド含有合成抑制剤 |
| JPH09176010A (ja) * | 1995-12-27 | 1997-07-08 | Kureha Chem Ind Co Ltd | Ｈｓｐ６０ファミリーに属するタンパク質のフラボノイド含有合成抑制剤 |
| US6506792B1 (en) | 1997-03-04 | 2003-01-14 | Sterix Limited | Compounds that inhibit oestrone sulphatase and/or aromatase and methods for making and using |
| ES2233998T3 (es) * | 1996-03-05 | 2005-06-16 | Sterix Limited | Compuestos que comprenden un grupo sulfamato. |
| AU5531599A (en) | 1998-09-01 | 2000-03-21 | Lg Chemical Ltd. | Novel cdk inhibitors having flavone structure |
| KR20000019716A (ko) * | 1998-09-15 | 2000-04-15 | 박호군 | 바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물 |
| JP2002541116A (ja) * | 1999-04-05 | 2002-12-03 | ジーグラー，ランディー，エイチ | 糖尿病の治療のための組成物及び方法 |
| WO2001021608A2 (en) * | 1999-09-23 | 2001-03-29 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Novel flavonoids |
| US6334998B1 (en) * | 1999-12-07 | 2002-01-01 | Parker Hughes Institute | Estrogens for treating ALS |
| EP1127572A3 (en) * | 2000-02-25 | 2003-05-02 | Basf Aktiengesellschaft | Use of flavones for treating cycloxygenase-2 mediated diseases |
| JP2002010753A (ja) * | 2000-04-24 | 2002-01-15 | Marukin Chuyu Co Ltd | オリーブ葉またはその抽出成分を含有するアミラーゼ阻害剤および高血糖者用食品 |
-
2002
- 2002-09-06 EP EP02798140A patent/EP1429750B1/en not_active Expired - Lifetime
- 2002-09-06 CN CN028204700A patent/CN1668287B/zh not_active Expired - Fee Related
- 2002-09-06 WO PCT/US2002/028348 patent/WO2003022994A2/en active Application Filing
- 2002-09-06 AU AU2002332878A patent/AU2002332878A1/en not_active Abandoned
- 2002-09-06 JP JP2003527059A patent/JP2005504796A/ja active Pending
- 2002-09-06 BR BR0212354-1A patent/BR0212354A/pt not_active IP Right Cessation
- 2002-09-06 US US10/236,861 patent/US6774142B2/en not_active Expired - Lifetime
- 2002-09-06 DE DE60237213T patent/DE60237213D1/de not_active Expired - Lifetime
- 2002-09-06 MX MXPA04002077A patent/MXPA04002077A/es not_active Application Discontinuation
- 2002-09-06 KR KR10-2004-7003414A patent/KR20040048407A/ko not_active Application Discontinuation
- 2002-09-06 AT AT02798140T patent/ATE476178T1/de not_active IP Right Cessation
-
2004
- 2004-05-04 US US10/838,766 patent/US20040209825A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003022994A2 (en) | 2003-03-20 |
| CN1668287A (zh) | 2005-09-14 |
| EP1429750A4 (en) | 2005-08-03 |
| EP1429750B1 (en) | 2010-08-04 |
| JP2005504796A (ja) | 2005-02-17 |
| KR20040048407A (ko) | 2004-06-09 |
| CN1668287B (zh) | 2012-03-28 |
| EP1429750A2 (en) | 2004-06-23 |
| DE60237213D1 (de) | 2010-09-16 |
| US20040209825A1 (en) | 2004-10-21 |
| AU2002332878A1 (en) | 2003-03-24 |
| US6774142B2 (en) | 2004-08-10 |
| MXPA04002077A (es) | 2005-02-17 |
| US20030069192A1 (en) | 2003-04-10 |
| WO2003022994A3 (en) | 2003-10-09 |
| ATE476178T1 (de) | 2010-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0212354A (pt) | Inibição por 3-deoxiflavonóides da ativação dos linfócitos-t e terapias relacionadas com ela | |
| TW200612934A (en) | Quaternary salt CCR2 antagonists | |
| NO20020792L (no) | Behandling av rastlöse ben syndrom med en kombinasjon av clonidin og opioid | |
| CY1110405T1 (el) | Φαρμακευτικες συνθεσεις περιλαμβανοντας δεξτρομεθορφανη και κινιδινη για την αγωγη νευρολογικων διαταραχων | |
| DK1263941T3 (da) | Xylanasevarianter med ændret sensitivitet overfor xylanaseinhibitorer | |
| WO2006089095A3 (en) | Treating neurological disorders | |
| DE60022152D1 (de) | Parallele optimierte Ereignisauslösung in parallelen Datenbanksystemen | |
| ATE478863T1 (de) | Heterotetracyclische verbindungen als tpo- mimetica | |
| DE60128912D1 (en) | Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika | |
| NO20064880L (no) | behandling av nevrologiske tilstander ved anvendelse av komplement C5a-reseptormodulatorer | |
| SG148198A1 (en) | Methods and reagents for the treatment of inflammatory disorders | |
| DE60134645D1 (de) | Amidinderivate als selektive nmda-rezeptorantagonisten | |
| ATE295928T1 (de) | Gleitschienentürschliesser | |
| WO2003094842A3 (en) | Conjugates comprising central nervous system active drug | |
| PT888330E (pt) | Metodos de tratamento ou prevencao de cistite intersticial | |
| AR046400A1 (es) | Sales de pantoprazol | |
| SI1537226T1 (sl) | Postopek za reproduciranje plevromutilinov | |
| TR200100240T2 (tr) | Anksiyete bozukluklarının tedavisi | |
| DE60333351D1 (de) | N-substituiertes benzothiophensulfonamidderivat | |
| ATE337704T1 (de) | Zusammensetzungen mit biostimulierender wirksamkeit | |
| FR2835436B1 (fr) | Instrumentation pour analgesie, notamment peridurale | |
| TR200402036T4 (tr) | (-)-Cis-2-(2-Klorofenil)-5, 7-Dihidroksi-8-[4R-(3S-Hidroksi-1-Metil) Piperidinil]-4H-1- Benzopiran-4-on'un psödopolimorfu | |
| PL1685849T3 (pl) | Inhibitory PDE 4 do leczenia śródmiąższowego zapalenia pęcherza moczowego | |
| EP1581759A4 (en) | METHODS OF TREATING TAXOL INDUCED SENSORY NEUROPATHY | |
| NO20004363L (no) | Anvendelse av D1-/D5-antagonister for behandling av tvangsforstyrrelser, somatoforme forstyrrelser, dissosiative forstyrrelser, impulskontrollforstyrrelser og autisme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2094 DE 22/02/2011. |